Nirmeen Elmadany

Dr. Nirmeen Elmadany

German Cancer Research Center, Heidelberg, Baden-Württemberg, Germany
orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2020 in Molecular Pharmacology
Verified
Journal Article
Closed access
PDF file
LGLobna Gharaibeh
Lobna Gharaibeh
NENirmeen Elmadany
Nirmeen Elmadany
KAKholoud Alwosaibai
Kholoud Alwosaibai
WAWalhan Alshaer
Walhan Alshaer
The Notch family consists of four highly conserved transmembrane receptors, the release of the active intracellular domain requires the enzymatic activity of gamma secretase. Notch is involved in embryonic development and in many physiological processes of normal cells where it regulates growth, apoptosis and differentiation. Notch 1, a member of the Notch family, is implicated in many types of cancer, including breast cancer (especially triple negative breast cancer), leukemias, brain tumors, and many others. Notch 1 is tightly connected to many signaling pathways that are therapeutically involved in tumorigenesis. Together, they impact apoptosis, proliferation, chemosensitivity, immune-response and the population of cancer stem cells. Notch 1 inhibition can be achieved through various and diverse methods, among the most common are the gamma secretase inhibitors which produce a pan-Notch inhibition, or the use of Notch 1 siRNA or Notch 1 monoclonal antibodies (mAb) which produce a more specific blockade. Downregulation of Notch 1 can be used alone or in combination with chemotherapy where a synergistic effect and a decrease in chemoresistance can be achieved. Targeting Notch1 in cancers that harbor high expression levels of Notch 1 offers an addition to therapeutic strategies recruited for managing cancer. Considering available evidence, Notch 1 offers a legitimate target that might be incorporated in future strategies for combating cancer. In this review, the possible clinical applications of Notch 1 inhibition and the obstacles that hinder its clinical application are discussed. Significance Statement Notch 1 plays an important role in different types of cancer. Numerous approaches of Notch 1 inhibition possess potential benefits in the management of various clinical aspects of cancer. The application of different Notch 1 inhibition modalities faces many challenges.

1 October 2019 in Brain, Behavior, and Immunity
Verified
Journal Article
Open access
VHVerena Haage
Verena Haage
NENirmeen Elmadany
Nirmeen Elmadany
LRLars Roll
Lars Roll
AFAndreas Faissner
Andreas Faissner
DGDavid H. Gutmann
David H. Gutmann
HKHelmut Kettenmann
Helmut Kettenmann
Tenascin C (Tnc) is an extracellular matrix glycoprotein, expressed in the CNS during development, as well as in the setting of inflammation, fibrosis and cancer, which operates as an activator of Toll-like receptor 4 (TLR4). Although TLR4 is highly expressed in microglia, the effect of Tnc on microglia has not been elucidated to date. Herein, we demonstrate that Tnc regulates microglial phagocytic activity at an early postnatal age (P4), and that this process is partially dependent on microglial TLR4 expression. We further show that Tnc regulates proinflammatory cytokine/chemokine production, chemotaxis and phagocytosis in primary microglia in a TLR4-dependent fashion. Moreover, Tnc induces histone-deacetylase 1 (HDAC1) expression in microglia, such that HDAC1 inhibition by MS-275 decreases Tnc-induced microglial IL-6 and TNF-α production. Finally, Tnc-/- cortical microglia have reduced HDAC1 expression levels at P4. Taken together, these findings establish Tnc as a regulator of microglia function during early postnatal development.

5 February 2016 in Asian Pacific Journal of Cancer Prevention
Verified
Journal Article
Open access
PDF file
AAAli M Abuhaliema
Ali M Abuhaliema
AYAl-Motassem Yousef
Al-Motassem Yousef
NENirmeen Elmadany
Nirmeen Elmadany
NBNailya R Bulatova
Nailya R Bulatova
NANemah M Awwad
Nemah M Awwad
KMKhalil Z Al Majdalawi
Khalil Z Al Majdalawi
Breast cancer is the leading cause of cancer death among women and the second in humans worldwide. Many published studies have suggested an association between MDR1 polymorphisms and breast cancer risk. Our aim was to study the association between genetic polymorphism of MDR1 at three sites (C3435T, G2677A/T, and C1236T) and their haplotype and the risk of breast cancer in Jordanian females. A case-control study involving 150 breast cancer cases and 150 controls was conducted. Controls were age-matched to cases. The polymerase chain reaction/restriction fragment length polymorphism (PCR- RFLP) technique and sequencing were performed to analyse genotypes. The distribution of MDR1 C3435T genotypes differed between cases and controls [cases, CC 45.3%, CT 41.3%, and TT 13.3%; controls, CC 13.4%, CT 43.3%, and TT 30.2%, p < 0.001]. Similarly, the distribution of G2677A/T significantly differed [cases, GG 43.1 %, GT+GA 50.9% and AA+TT 6%; controls, GG 29.6 %, GT+GA 50.9%, and AA+TT 19.4%, p = 0.004]. On the other hand, genotype and allelotype distribution of C1236T was not statistically different between cases and controls (p=0.56 and 0.26, respectively). The CGC haplotype increased the risk to breast cancer by 2.5-fold compared to others, while TGC and TTC haplotypes carried 2.5- and 5-fold lower risk of breast cancer, respectively. Genetic polymorphisms of MDR1 C3435T and G2677A/T, but not C1236T, are associated with increased risk of breast cancer. In addition, CGC, TGC and TTC haplotypes have different impacts on the risk of breast cancer. Future, larger studies are needed to validate these findings.

14 February 2020 in Journal of Neuroscience
Verified
Journal Article
Open access
PDF file
NENirmeen Elmadany
Nirmeen Elmadany
FSFelipe de Almeida Sassi
Felipe de Almeida Sassi
SWStefan Wendt
Stefan Wendt
FLFrancesca Logiacco
Francesca Logiacco
JVJosien Visser
Josien Visser
MSMarcus Semtner
Marcus Semtner
Microglial cells are considered as sensors of brain pathology by detecting any sign of brain lesions, infections, or dysfunction and can influence the onset and progression of neurological diseases. They are capable of sensing their neuronal environment via many different signaling molecules, such as neurotransmitters, neurohormones and neuropeptides. The neuropeptide VGF has been associated with many metabolic and neurological disorders. TLQP21 is a VGF-derived peptide and has been shown to signal via C3aR1 and C1qBP receptors. The effect of TLQP21 on microglial functions in health or disease is not known. Studying microglial cells in acute brain slices, we found that TLQP21 impaired metabotropic purinergic signaling. Specifically, it attenuated the ATP-induced activation of a K+conductance, the UDP-stimulated phagocytic activity, and the ATP-dependent laser lesion-induced process outgrowth. These impairments were reversed by blocking C1qBP, but not C3aR1 receptors. While microglia in brain slices from male mice lack C3aR1 receptors, both receptors are expressed in primary cultured microglia. In addition to the negative impact on purinergic signaling, we found stimulating effects of TLQP21 in cultured microglia, which were mediated by C3aR1 receptors: it directly evoked membrane currents, stimulated basal phagocytic activity, evoked intracellular Ca2+transient elevations, and served as a chemotactic signal. We conclude that TLQP21 has differential effects on microglia depending on C3aR1 activation or C1qBP-dependent attenuation of purinergic signaling. Thus, TLQP21 can modulate the functional phenotype of microglia, which may have an impact on their function in health and disease.SIGNIFICANCE STATEMENTThe neuropeptide VGF and its peptides have been associated with many metabolic and neurological disorders. TLQP21 is a VGF-derived peptide that activates C1qBP receptors, which are expressed by microglia. We show here, for the first time, that TLQP21 impairs P2Y-mediated purinergic signaling and related functions. These include modulation of phagocytic activity and responses to injury. As purinergic signaling is central for microglial actions in the brain, this TLQP21-mediated mechanism might regulate microglial activity in health and disease. We furthermore show that, in addition to C1qBP, functional C3aR1 responses contribute to TLQP21 action on microglia. However, C3aR1 responses were only present in primary cultures but notin situ, suggesting that the expression of these receptors might vary between different microglial activation states.

19 July 2022 in Biomedicines
Verified
Journal Article
Open access
PDF file
NENirmeen Elmadany
Nirmeen Elmadany
OAObada T. Alhalabi
Obada T. Alhalabi
MPMichael Platten
Michael Platten
LBLukas Bunse
Lukas Bunse
Immunotherapy has revolutionized cancer treatment. Despite the recent advances in immunotherapeutic approaches for several tumor entities, limited response has been observed in malignant gliomas, including glioblastoma (GBM). Conversely, one of the emerging immunotherapeutic modalities is chimeric antigen receptors (CAR) T cell therapy, which demonstrated promising clinical responses in other solid tumors. Current pre-clinical and interventional clinical studies suggest improved efficacy when CAR-T cells are delivered locoregionally, rather than intravenously. In this review, we summarize possible CAR-T cell administration routes including locoregional therapy, systemic administration with and without focused ultrasound, direct intra-arterial drug delivery and nanoparticle-enhanced delivery in glioma. Moreover, we discuss published as well as ongoing and planned clinical trials involving CAR-T cell therapy in malignant glioma. With increasing neoadjuvant and/or adjuvant combinatorial immunotherapeutic concepts and modalities with specific modes of action for malignant glioma, selection of administration routes becomes increasingly important.

1 December 2018 in Infrared Physics & Technology
Verified
Journal Article
Closed access
NENirmeen Elmadany
Nirmeen Elmadany
EKEnam A. Khalil
Enam A. Khalil
Lisa VaccariLisa Vaccari
Lisa Vaccari
GBGiovanni Birarda
Giovanni Birarda
IYIbraheem Yousef
Ibraheem Yousef
RARana Abu-Dahab
Rana Abu-Dahab